Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: ASCO Guideline Update.

ABSTRACT:

Purpose

To provide updated guidance regarding neoadjuvant chemotherapy (NACT) and primary cytoreductive surgery (PCS) among patients with stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer (epithelial ovarian cancer [EOC]).

Methods

A multidisciplinary Expert Panel convened and updated the systematic review.

Results

Sixty-one studies form the evidence base.

Recommendations

Patients with suspected stage III-IV EOC should be evaluated by a gynecologic oncologist, with cancer antigen 125, computed tomography of the abdomen and pelvis, and chest imaging included. All patients with EOC should be offered germline genetic and somatic testing at diagnosis. For patients with newly diagnosed advanced EOC who are fit for surgery and have a high l

SUBMITTER: Gaillard S 

PROVIDER: S-EPMC11934100 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature